Business Description
Yumanity Therapeutics Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
42P.GermanyYMTX.USA IPO Date
2020-12-23Description
Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 41.26 | |||||
| Equity-to-Asset | 0.57 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | -37.09 | |||||
| Beneish M-Score | -4.69 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.7 | |||||
| 9-Day RSI | 50.38 | |||||
| 14-Day RSI | 51.71 | |||||
| 6-1 Month Momentum % | 15.8 | |||||
| 12-1 Month Momentum % | -41.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.21 | |||||
| Quick Ratio | 2.21 | |||||
| Cash Ratio | 2.05 | |||||
| Days Sales Outstanding | 376.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -562.84 | |||||
| Net Margin % | -660.61 | |||||
| ROE % | -197.35 | |||||
| ROA % | -84.5 | |||||
| ROIC % | -139.51 | |||||
| ROC (Joel Greenblatt) % | -304.79 | |||||
| ROCE % | -122.65 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.2 | |||||
| PB Ratio | 3.75 | |||||
| Price-to-Tangible-Book | 3.78 | |||||
| EV-to-EBIT | -0.4 | |||||
| EV-to-EBITDA | -0.4 | |||||
| EV-to-Revenue | 2.54 | |||||
| EV-to-FCF | -0.48 | |||||
| Price-to-Net-Current-Asset-Value | 4.11 | |||||
| Price-to-Net-Cash | 4.73 | |||||
| Earnings Yield (Greenblatt) % | -250 |
Balance Sheet Breakdown
Cashflow Statement Breakdown
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:YMTX
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Yumanity Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4.844 | ||
| EPS (TTM) ($) | -3 | ||
| Beta | 0 | ||
| Volatility % | 108.83 | ||
| 14-Day RSI | 51.71 | ||
| 14-Day ATR ($) | 0.165807 | ||
| 20-Day SMA ($) | 1.877325 | ||
| 12-1 Month Momentum % | -41.73 | ||
| 52-Week Range ($) | 0.95 - 3.7789 | ||
| Shares Outstanding (Mil) | 10.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Yumanity Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Yumanity Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Yumanity Therapeutics Inc Frequently Asked Questions
What is Yumanity Therapeutics Inc(YMTX)'s stock price today?
The current price of YMTX is $1.89. The 52 week high of YMTX is $3.78 and 52 week low is $0.95.
When is next earnings date of Yumanity Therapeutics Inc(YMTX)?
The next earnings date of Yumanity Therapeutics Inc(YMTX) is 2023-08-12 Est..
Does Yumanity Therapeutics Inc(YMTX) pay dividends? If so, how much?
Yumanity Therapeutics Inc(YMTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
